Efficacy and safety of upadacitinib in psoriatic arthritis

Psoratic arthritis (PsA) is a common disorder affecting every fifth patient with psoriasis. Typical clinical manifestations of PsA include asymmetric mono/oligoathritis or polyarthritis, spondyloarthritis, enthesitis and dactylitis. More rarely associated uveitis inflammatory bowel disease. Upadacitinib selective JAK-kinase inhibitor approved for treatment PsA. Its efficacy favorable safety profile in patients were established two randomized placebocontrolled phase 3 trials (SELECT-PsA 1 2). In both studies, upadacitinib was significantly more effective than placebo improved activity PsA, psoriatic lesions, Moreover, axial spondylitis and, therefore, can be used any The authors present cases discuss indications administration such patients.